UBS Group’s IVERIC bio ISEE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-21,000
Closed -$826K – 10349
2023
Q2
$826K Buy
+21,000
New +$741K ﹤0.01% 4406
2017
Q1
– Sell
-4,400
Closed -$21K – 8094
2016
Q4
$21K Buy
+4,400
New +$131K ﹤0.01% 6491
2015
Q3
– Sell
-50,000
Closed -$2.6M – 8720
2015
Q2
$2.6M Buy
+50,000
New +$2.49M ﹤0.01% 2724

UBS Group's ISEE Position: Q3 2023 in Review

UBS Group sold out of IVERIC bio (ISEE) in Q3 2023, closing a stake of 10,431 shares — an estimated $410K sold.

UBS Group first reported a position in ISEE in Q4 2014 and held it in 35 quarters. The position peaked at $5.79M in Q4 2022. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

  • UBS Group reported no remaining IVERIC bio position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 10,431 IVERIC bio shares in Q3 2023, an estimated $410K.
  • UBS Group first reported a position in IVERIC bio in Q4 2014 and held it in 35 quarters.
  • UBS Group's IVERIC bio position peaked at $5.79M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held IVERIC bio as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.